Alvotech (ALVO) Capital Expenditures (2022 - 2026)
Alvotech's (ALVO) quarterly Capital Expenditures came in at -$7.1 million in Q1 2026, up 69.2% YoY from -$4.2 million in Q1 2025, and down 105.94% on a QoQ basis from $120.2 million in Q4 2025.
Alvotech (ALVO) Capital Expenditures (2022 - 2026) Analysis & Trends
Alvotech (ALVO) has 5 years of Capital Expenditures data on file, last reported at -$7.1 million in Q1 2026.
- Quarterly Capital Expenditures rose 69.2% year-over-year to -$7.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $80.5 million (up 183.12% YoY) and the FY2025 annual result came in at $64.5 million, up 20.14% from the prior year.
- Capital Expenditures fell to -$7.1 million in Q1 2026, from $120.2 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $120.2 million in Q4 2025 to a low of -$53.7 million in Q4 2024.
- A 5-year average of -$8.8 million and a median of -$13.6 million in 2025 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 324.0% in 2025, down 469.85% in 2025.
- Tracing ALVO's Capital Expenditures over 5 years: stood at -$37.9 million in 2022, then gained by 12.27% to -$33.2 million in 2023, then sank by 61.46% to -$53.7 million in 2024, then jumped by 324.0% to $120.2 million in 2025, then tumbled by 105.94% to -$7.1 million in 2026.
- The last three Capital Expenditures figures came in at -$7.1 million (Q1 2026), $120.2 million (Q4 2025), and -$18.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.08 Bn | 39.43 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.54 Bn | 29.87 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.60 Bn | 22.80 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.50 Bn | 15.11 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.69 Bn | 11.16 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.96 Bn | - | - |
| 10 | Alvotech | 1.23 Bn | 1.23 Bn | 5.09 Mn | -7.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.14 Mn |
| Mar 31, 2026 | -7.14 Mn |
| Dec 31, 2025 | 120.20 Mn |
| Dec 31, 2025 | 120.20 Mn |
| Sep 30, 2025 | -18.93 Mn |
| Sep 30, 2025 | -18.93 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Jun 30, 2025 | -13.62 Mn |
| Mar 31, 2025 | -23.19 Mn |
| Mar 31, 2025 | -23.19 Mn |
| Dec 31, 2024 | -53.66 Mn |
| Dec 31, 2024 | -53.66 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Sep 30, 2024 | -13.82 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Jun 30, 2024 | -6.20 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Mar 31, 2024 | -4.07 Mn |
| Dec 31, 2023 | -33.23 Mn |
| Dec 31, 2023 | -33.23 Mn |